OS
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Tom Waddell, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Sergio Jobim de Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Sterling Wu, Julia Markensohn, Yiwei Zhang, Andrey Loboda, Amir Vajdi, Rodolfo F Perini, Joseph Burgents, Thomas Powles
Nat Med 31(10) 3475-3484
At the first interim analysis of the phase 3 KEYNOTE-426 trial, first-line pembrolizumab plus axitinib showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) over sunitinib for advanced renal cell carcinoma (RCC). To assess long-term durability of clinical outcomes and elucidate predictive biomarkers for RCC, we performed efficacy and prespecified exploratory biomarker analyses from KEYNOTE-426 with ≥5 years of follow-up. Pembrolizumab plus axitinib showed sustained benefits in OS (hazard ratio: 0.84; 95% confidence interval: 0.71-0.99), PFS (hazard ratio: 0.69; 95% confidence interval: 0.59-0.81) and ORR (60.6% versus 39.6%) compared to sunitinib. An 18-gene T-cell-inflamed gene expression profile (TcellinfGEP) was positively associated with OS (P = 0.002), PFS (P < 0.0001) and ORR (P < 0.0001) within the pembrolizumab plus axitinib arm. An angiogenesis signature was positively associated with OS (P = 0.004) within the pembrolizumab plus axitinib arm and with OS (P < 0.0001), PFS (P < 0.001) and ORR (P = 0.002) within the sunitinib arm. Across arms, programmed cell death ligand 1 combined positive score was only associated (negatively) with OS within the sunitinib arm (P = 0.025). Additionally, PBRM1 (polybromo-1) mutation had a positive association with ORR (P = 0.002) within the pembrolizumab plus axitinib arm. Within the sunitinib arm, OS was positively associated with VHL (von Hippel-Lindau tumor suppressor gene) (P = 0.040) and PBRM1 (P = 0.010) mutations and was negatively associated with BAP1 (BRCA1-associated protein 1) mutation (P = 0.019). Results showed a sustained clinical benefit with pembrolizumab plus axitinib over sunitinib and provide valuable information on biomarkers for immunotherapy-based treatment combinations in advanced RCC. Prospective clinical investigations are needed for biomarker-directed treatment for advanced RCC. ClinicalTrials.gov identifier: NCT02853331 .
6 个 Figure · 27 个 KM 面板
Fig. 2. OS, PFS and DOR in the intention-to-treat population. a , Kaplan–Meier estimates of OS. b , Kaplan–Meier estimates of PFS. c , OS by subgroups. d , PFS by subgroups. e , Kaplan–Meier estimates of DOR in participants with a confirmed objective response. In a , b and e , tick marks represent censored data. In c and d , shaded squares correspond to the hazard ratios (HRs), and the error bars (horizontal lines) correspond to the 95% confidence intervals (CIs).
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel E
Panel E 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. Kaplan–Meier estimates of survival by Tcell inf GEP or angiogenesis signature cutoff. a , OS by Tcell inf GEP cutoff. b , PFS by Tcell inf GEP cutoff. c , OS by angiogenesis signature cutoff. d , PFS by angiogenesis signature cutoff. Tick marks represent censored data. CI, confidence interval; HR, hazard ratio.
Fig. 4 · Panel A
Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel A_2
Panel A_2 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel B
Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel B_4
Panel B_4 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel C
Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel C_6
Panel C_6 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel D
Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel D_8
Panel D_8 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4. Kaplan-Meier estimates of survival by VHL mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using a Cox proportional hazards model, with adjustment for IMDC risk category. Tick marks represent censored data. HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; OS, overall survival; PFS, progression-free survival; VHL , von Lindau-Hippel tumor suppressor gene; WT, wild type.
Extended Data Fig. 4 · Panel A
Panel A 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4 · Panel A_2
Panel A_2 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4 · Panel B
Panel B 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4 · Panel B_4
Panel B_4 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5. Kaplan-Meier estimates of survival by PBRM1 mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using the Cox proportional hazards model, with adjustment for IMDC risk category. HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NE, not evaluable; OS, overall survival; PBRM1 , polybromo-1 gene; PFS, progression-free survival; WT, wild type.
Extended Data Fig. 5 · Panel A
Panel A 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel A_2
Panel A_2 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel B
Panel B 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel B_4
Panel B_4 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 6. Kaplan-Meier estimates of survival by SETD2 mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using the Cox proportional hazards model, with adjustment for IMDC risk category. HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; OS, overall survival; PFS, progression-free survival; SETD2 , SET domain containing 2, histone lysine methyltransferase gene; WT, wild type.
Extended Data Fig. 6 · Panel A
Panel A 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 6 · Panel A_2
Panel A_2 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 6 · Panel B
Panel B 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 6 · Panel B_4
Panel B_4 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7. Kaplan-Meier estimates of survival by BAP1 mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using the Cox proportional hazards model, with adjustment for IMDC risk category. BAP1 , BRCA1 -associated protein 1 gene; HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; OS, overall survival; PFS, progression-free survival; WT, wild type.
Extended Data Fig. 7 · Panel A
Panel A 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel A_2
Panel A_2 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel B
Panel B 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel B_4
Panel B_4 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。